Clinical Risk Assessment and Prediction
Clinical Risk Assessment and Prediction
批准号:
8668334
负责人:
THOMAS L VAUGHAN
金额:
$24.79万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-08-16 至 2019-03-31
关键词:
AblationAccountingAddressBarrett EpitheliumBarrett EsophagusBiological AssayBiopsyBloodCancer ControlCaringClinicalClinical ResearchComplicationComputer SimulationCoupledDataDiseaseDysplasiaEnrollmentEnvironmental Risk FactorEpitheliumEsophagealEsophageal AdenocarcinomaEsophageal TissueEsophagusExcisionFundoplicationGenetic Predisposition to DiseaseGenomicsGenotypeIncidenceIndividualInstructionIntegration Host FactorsJointsMalignant NeoplasmsManuscriptsMeasuresMedicalMedical RecordsMethodsModelingMolecular AbnormalityMorbidity - disease rateNon-Steroidal Anti-Inflammatory AgentsOperative Surgical ProceduresOutcomeParticipantPatientsPersonsPharmaceutical PreparationsPopulationPredictive ValuePredispositionPreventionPrevention ProtocolsPrevention programProton Pump InhibitorsPublic HealthPublishingRadiofrequency Interstitial AblationRefluxResearchResearch PersonnelResourcesRiskRisk AssessmentRouteSensitivity and SpecificitySerumSeveritiesSiteStagingSurveillance ProgramTechniquesTimeValidationWorkbasecancer preventionclinical decision-makingclinical practiceclinical riskcohortcost effectivedensityevidence basegenome wide association studygenome-widehazardhigh riskimprovedinnovationmortalitypreventresponsetooltumor progression
中文摘要
食管腺癌(EA)的死亡率在过去40年里急剧上升。努力实现以下目标
预防和控制反映了巴雷特食道(BE)作为一种
反流的并发症,并极易发生EA;因此,医疗护理的重点是确定
来自反流患者中的患者,将他们纳入长期监测,并积极
在他们患浸润性癌症之前对他们进行治疗。然而,EA死亡率的持续上升,加上
95%的BE患者永远不会进展为癌症的事实,突显了这一点的无效
接近。项目2直接建立在P01团队最近取得的进展之上,以解决
更有效的防控方案。在过去的5年里,我们发表或提交了41
关于项目2的问题和目标的研究手稿。在续期期间,我们将利用富人
和POL的全面数据资源(包括宿主和环境风险因素、医疗
记录、血清分析、高密度基因分型和食道活检)在BE上预期收集
600名参与者组成的队列,有77项电针结果。在目标1中,我们将开发定制的风险和预测模型
对于电针的绝对风险,这将对临床决策有用。在目标2中,我们将评估总结
关于体细胞基因组改变(SGA)的全基因组测量及其增加的预测价值。在……里面
作为一个探索性的目标,我们将研究一种有争议的新疗法--射频消融术--对
高危患者的基因组异常。在目标3中,我们将把目标1的结果与SGA合并
平台,并使用计算机模拟来考虑与时间相关的疾病动力学
制定和评估优化的监测和预防方案。结果将与以下人员共享
利用信标联盟的资源参与早期阶段风险评估的调查人员,
并随着时间的推移通过与其他队列的交叉验证来改进。项目2寻求
在整个POL期间巩固和推广关键发现,以推进临床实践和
加强EA防控。
相关性(请参阅说明):
食管腺癌的发病率比任何其他癌症上升得都快。我们建议解决以下问题
通过开发和广泛提供一套预防和控制这种癌症的重要障碍
用于Barrett‘s食道风险预测和监测的临床工具将在
公共卫生、临床和研究环境。
英文摘要
Mortality from esophageal adenocarcinoma (EA) has risen dramatically over four decades. Efforts towards
prevention and control have reflected the prevailing paradigm that Barrett's esophagus (BE) arises as a
complication of reflux and greatly predisposes to EA; consequently medical care has focused on identifying
persons with BE from among those with reflux, enrolling them in long-term surveillance, and aggressively
treating them before they develop invasive cancer. However, the continued increase in EA mortality, coupled
with the fact that 95% of BE patients will never progress to cancer, underscores the ineffectiveness of this
approach. Project 2 builds directly on recent advances made by the P01 team to address critical barriers to a
more effective program of prevention and control. In the past 5 years, we have published or submitted 41
research manuscripts addressing Project 2 issues and aims. During the renewal period we will utilize the rich
and comprehensive data resources ofthe POl (including host and environmental risk factors, medical
records, serum assays, high-density genotyping, and esophageal biopsies) collected prospectively on a BE
cohort of 600 participants with 77 EA outcomes. In aim 1 we will develop risk and prediction models tailored
to the absolute risk of EA that will be useful for clinical decision-making. In aim 2 we will evaluate summary
genome-wide measures of somatic genomic alterations (SGA) with regard to their added predictive value. In
an exploratory aim we will examine the effects of a controversial new treatment, radio frequency ablation, on
genomic abnormalities in high-risk patients. In aim 3 we will consolidate the results from aim 1 with the SGA
platform from aim 2, and use computer simulation to take into account time-dependent disease dynamics to
develop and evaluate an optimized surveillance and prevention protocol. Results will be shared with
investigators involved with risk assessment of eariier stages using resources of the BEACON consortium,
and improved over time by cross-validation with other cohorts as they develop. Project 2 seeks to
consolidate and extend key discoveries over the entire period of the POl to advance clinical practice and
improve EA prevention and control.
RELEVANCE (See instructions):
The incidence of esophageal adenocarcinoma is rising faster than any other cancer. We propose to address
important barriers to prevention and control of this cancer by developing and making broadly available a set
of clinical tools for risk prediction and surveillance of Barrett's esophagus to be validated and applied in
public health, clinical and research settings.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
METABOLITE BIOIMARKERS IN THE DEVELOPMENT OF ESOPHAGEAL ADENOCARCINOMA
-
批准号:8571375
-
项目类别:
-
资助金额:$24.76万
-
财政年份:2013
-
负责人:THOMAS L VAUGHAN
-
依托单位:
METABOLITE BIOIMARKERS IN THE DEVELOPMENT OF ESOPHAGEAL ADENOCARCINOMA
-
批准号:8726352
-
项目类别:
-
资助金额:$18.46万
-
财政年份:2013
-
负责人:THOMAS L VAUGHAN
-
依托单位:
Barrett's and Esophageal Adenocarcinoma Genetic Susceptibility Study (BEAGESS)
-
批准号:8145246
-
项目类别:
-
资助金额:$123.08万
-
财政年份:2009
-
负责人:THOMAS L VAUGHAN
-
依托单位:
Barrett's and Esophageal Adenocarcinoma Genetic Susceptibility Study (BEAGESS)
-
批准号:7730733
-
项目类别:
-
资助金额:$344.89万
-
财政年份:2009
-
负责人:THOMAS L VAUGHAN
-
依托单位:
Barrett's and Esophageal Adenocarcinoma Genetic Susceptibility Study (BEAGESS)
-
批准号:8017939
-
项目类别:
-
资助金额:$198.35万
-
财政年份:2009
-
负责人:THOMAS L VAUGHAN
-
依托单位:
Established Investigator Award in Cancer Prevention and Control
-
批准号:7629722
-
项目类别:
-
资助金额:$15.36万
-
财政年份:2007
-
负责人:THOMAS L VAUGHAN
-
依托单位:
Established Investigator Award in Cancer Prevention and Control
-
批准号:8098685
-
项目类别:
-
资助金额:$15.4万
-
财政年份:2007
-
负责人:THOMAS L VAUGHAN
-
依托单位:
Established Investigator Award in Cancer Prevention and Control
-
批准号:7923553
-
项目类别:
-
资助金额:$10.8万
-
财政年份:2007
-
负责人:THOMAS L VAUGHAN
-
依托单位:
ESTABLISHED INVESTIGATOR AWARD IN CANCER PREVENTION AND CONTROL
-
批准号:8702923
-
项目类别:
-
资助金额:$15.12万
-
财政年份:2007
-
负责人:THOMAS L VAUGHAN
-
依托单位:
EPIDEMIOLOGY OF PROGRESSION IN BARRETT'S ESOPHAGUS
-
批准号:7305720
-
项目类别:
-
资助金额:$26.16万
-
财政年份:2007
-
负责人:THOMAS L VAUGHAN
-
依托单位:
Established Investigator Award in Cancer Prevention and Control
-
批准号:7878656
-
项目类别:
-
资助金额:$15.4万
-
财政年份:2007
-
负责人:THOMAS L VAUGHAN
-
依托单位:
ESTABLISHED INVESTIGATOR AWARD IN CANCER PREVENTION AND CONTROL
-
批准号:8522164
-
项目类别:
-
资助金额:$15.12万
-
财政年份:2007
-
负责人:THOMAS L VAUGHAN
-
依托单位:
ESTABLISHED INVESTIGATOR AWARD IN CANCER PREVENTION AND CONTROL
-
批准号:8384552
-
项目类别:
-
资助金额:$15.12万
-
财政年份:2007
-
负责人:THOMAS L VAUGHAN
-
依托单位:
Established Investigator Award in Cancer Prevention and Control
-
批准号:7321857
-
项目类别:
-
资助金额:$15.03万
-
财政年份:2007
-
负责人:THOMAS L VAUGHAN
-
依托单位:
Established Investigator Award in Cancer Prevention and Control
-
批准号:7473907
-
项目类别:
-
资助金额:$15.3万
-
财政年份:2007
-
负责人:THOMAS L VAUGHAN
-
依托单位:
ESTABLISHED INVESTIGATOR AWARD IN CANCER PREVENTION AND CONTROL
-
批准号:9129605
-
项目类别:
-
资助金额:$15.12万
-
财政年份:2007
-
负责人:THOMAS L VAUGHAN
-
依托单位:
CORE--Environmental Carcinogenesis
-
批准号:6876446
-
项目类别:
-
资助金额:$1.18万
-
财政年份:2005
-
负责人:THOMAS L VAUGHAN
-
依托单位:
Insulin-like Growth Factors & Esophageal Adenocarcinoma
-
批准号:6667105
-
项目类别:
-
资助金额:$8.65万
-
财政年份:2002
-
负责人:THOMAS L VAUGHAN
-
依托单位:
Insulin-like Growth Factors & Esophageal Adenocarcinoma
-
批准号:6589236
-
项目类别:
-
资助金额:$8.65万
-
财政年份:2002
-
负责人:THOMAS L VAUGHAN
-
依托单位:
EPIDEMIOLOGY OF BARRETTS ESOPHAGUS
-
批准号:6172847
-
项目类别:
-
资助金额:$54.27万
-
财政年份:1997
-
负责人:THOMAS L VAUGHAN
-
依托单位:
海外基金